FDA, ap and personalized genetic medicines
Digest more
The guidance encourages the use of Bayesian statistics in drug trials. Instead of starting from scratch and only adding new information from the trial, the framework allows researchers to incorporate ...
The FDA has opened the door to the use of Bayesian statistical methods in clinical trials. The worry: Introducing ...
Explore the debate surrounding animal testing as new methods may jeopardise patient safety if not properly validated.
As regulatory authorities accelerate the use of New Approach Methodologies (NAMs), the drug discovery landscape is changing dramatically. This webinar explores how NAMs, immunology-driven ...
Replacing animal testing with alternate methodologies in preclinical drug trials holds potential for the development of cheaper, safer pharmaceuticals as well as alleviating animal suffering. But ...
Although new approach methodologies (NAMs) are not that new, they remain a crucial and evolving aspect of the development and production of biopharmaceuticals. “NAMs have been around for 20 ...
New approach methodologies (NAMs) – such as organoids, spheroids and microfluidic chip systems – aim to streamline early-stage drug discovery and revolutionize preclinical testing by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results